查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1965971

寵物疫苗市場－全球產業規模、佔有率、趨勢、機會和預測：按動物類型、疫苗類型、給藥方法、地區和競爭格局分類，2021-2031年

Pet Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Animal Type, By Vaccination, By Mode Of Administration, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球寵物疫苗市場預計將從 2025 年的 21.4 億美元成長到 2031 年的 30.9 億美元，複合年成長率為 6.31%。

這些生物製藥旨在激發伴侶動物的免疫反應，產生抗體，從而增強其對多種病毒、細菌和寄生蟲性行為感染的免疫力。成長要素的關鍵因素包括通用感染疾病風險的增加以及全球寵物飼養量的激增，凸顯了定期預防性獸醫護理的必要性。此外，政府對狂犬病控制的嚴格監管以及寵物人性化的趨勢也促使人們更加遵守疫苗接種計劃。例如，根據澳洲動物醫學協會發布的《2025年報告》，73%的澳洲家庭擁有寵物，顯示已開發地區高寵物飼養率正在推動對獸用生技藥品的需求。

市場概覽
預測期 2027-2031
市場規模：2025年 21.4億美元
市場規模：2031年 30.9億美元
複合年成長率：2026-2031年 6.31%
成長最快的細分市場 口服
最大的市場 北美洲

然而，獸醫服務成本的不斷上漲常常阻礙市場發展，這對注重預算的寵物飼主構成了巨大的經濟負擔。常規健康檢查和疫苗接種的高昂費用常常導致治療延誤，並難以堅持每年的加強免疫接種計劃。這種經濟壓力，加上長途運輸過程中維持低溫運輸的物流挑戰，仍是全球寵物疫苗市場持續成長的主要障礙。

市場促進因素

伴侶動物日益人性化是推動市場擴張的主要動力，顯著影響人們對預防性醫療保健解決方案的需求以及疫苗接種計劃的依從性。隨著飼主越來越將寵物視為家庭成員，他們對寵物健康和壽命的重視程度也日益提高，促使人們更加嚴格地遵守細菌和病毒威脅的疫苗接種通訊協定。這種文化轉變有效地擴大了生物製藥的潛在市場，確保了更多寵物獲得定期照護。寵物數量龐大；根據2024年3月發布的《英國寵物食品和寵物數據報告2024》，英國寵物總數已達3600萬隻，凸顯了需要定期獸醫護理的動物數量龐大。

同時，獸醫保健產業的成長也推動了市場發展，促進了優質創新疫苗產品的廣泛應用。飼主越來越願意在醫療服務上投入大量資金，這抵消了潛在的成本障礙，並推動了產業價值的成長。根據美國寵物用品協會於2025年3月發布的《2025年產業趨勢報告》，美國每年在獸醫保健和產品銷售方面的支出預計將達到414億美元，顯示人們對維護動物健康有著濃厚的興趣。與獸醫專業人士的積極互動進一步增強了這項經濟貢獻。根據澳洲動物醫學協會於2025年9月發布的《澳洲寵物2025》報告，89%的犬隻和75%的貓在過去一年中曾就診於獸醫，這表明較高的就診率，從而確保了製造商的持續收入。

市場挑戰

獸醫服務成本的不斷上漲是全球寵物疫苗市場擴張的主要障礙。隨著日常動物保健費用的增加，精打細算的飼主越來越傾向於選擇緊急治療而非疫苗接種等預防措施。這種經濟壓力阻礙了有效免疫計劃所需的持續護理，導致疫苗接種總量下降。當健康檢查費用過高時，飼主往往會推遲這些必要的就診，使獸醫錯失了為寵物接種必要的年度加強疫苗以維持免疫水平的機會。

因此，預防保健的延誤會直接導致市場需求萎縮。如果飼主未能遵守建議的疫苗接種計劃，群體免疫力就會受損，疫苗生產商的產生收入也會停滯不前。根據美國獸醫協會（AVMA）2025年的數據，獸醫服務價格上漲了5.7%，而就診患者數量較去年同期下降了3%。成本上升與診所就診量下降之間的這種相關性表明，經濟問題正在嚴重阻礙該行業在已開發地區和新興地區保持穩定成長的能力。

市場趨勢

慢性疾病治療性疫苗的商業化正在從根本上改變全球寵物疫苗市場，將免疫接種的重點從預防感染疾病擴展到主動管理複雜的非傳染性疾病，例如腫瘤。製造商正積極利用自體和精準免疫療法技術開發生物製藥，以激發伴侶動物的免疫系統攻擊腫瘤特異性抗原。這項臨床進展為獸醫提供了針對末期疾病的有效介入方案，而先前針對末期病患的治療選擇十分有限。例如，Toligen Pharmaceuticals公司於2025年2月發布的新聞稿題為“寵物抗癌新希望”，其中指出，接受該公司靶向自體癌症疫苗治療的轉移性血管肉瘤犬的總體生存率比僅接受手術的犬組提高了3.5倍，這凸顯了老年寵物對治療性生技藥品日益成長的依賴性。

同時，隨著重組疫苗和次單位疫苗平台的發展，產業格局也在發生變化，越來越多的公司為了提高安全性和擴大生產規模，開始放棄傳統的活病毒疫苗技術。這一趨勢凸顯了高純度抗原和高分子量生技藥品的研發，而對生物製程基礎設施的大量資本投入對於確保供應鏈穩定至關重要。主要企業的努力也體現了這種向先進平台技術的策略轉型。 2025年5月，默克動物保健公司宣布投資8.95億美元擴建位於堪薩斯州德索託的工廠，以提高其高分子量疫苗和生技藥品的產能。此類投資凸顯了市場對先進遞送系統的關注，這些系統能夠提高疫苗的療效並降低伴侶動物的副作用風險。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球寵物疫苗市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 動物種類（狗、貓、馬）
    • 疫苗類型（犬類、貓科動物、其他）
    • 依給藥途徑（注射疫苗、經鼻吸入型疫苗）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美寵物疫苗市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲寵物疫苗市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區寵物疫苗市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲寵物疫苗市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美寵物疫苗市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球寵物疫苗市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Zoetis Inc.
  • Bioveta as
  • Hester Biosciences Limited
  • Boehringer Ingelheim International GmbH
  • Brilliant Bio Pharma Private Limited
  • Heska Corporation
  • Merck & Co., Inc.
  • Virbac SA
  • Zendal Group
  • Elanco Animal Health Incorporated

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 19025

The Global Pet Vaccine Market is projected to expand from a valuation of USD 2.14 Billion in 2025 to USD 3.09 Billion by 2031, registering a CAGR of 6.31%. These biological preparations are engineered to trigger immune responses in companion animals, generating antibodies that confer immunity against various viral, bacterial, and parasitic infections. Key growth factors include the increasing incidence of zoonotic risks and a surge in global pet adoption, which underscores the need for regular preventative veterinary attention. Additionally, strict government regulations concerning rabies control, alongside the trend of pet humanization, drive higher adherence to vaccination schedules. For instance, Animal Medicines Australia reported in 2025 that 73% of Australian households possessed a pet, highlighting the strong ownership rates that fuel demand for veterinary biologicals in developed regions.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 2.14 Billion
Market Size 2031USD 3.09 Billion
CAGR 2026-20316.31%
Fastest Growing SegmentOral
Largest MarketNorth America

However, market progress is often hindered by the rising expense of veterinary services, which creates economic obstacles for budget-conscious pet owners. The substantial costs linked to routine wellness check-ups and vaccine administration frequently result in delayed treatments or failure to adhere to annual booster timelines. This financial limitation, combined with logistical difficulties in preserving cold-chain integrity during transport to isolated regions, persists as a major impediment to the consistent expansion of the global pet vaccine sector.

Market Driver

The increasing humanization of companion animals serves as a major engine for market expansion, heavily impacting the demand for preventative health solutions and adherence to immunization plans. As owners increasingly regard their pets as essential family members, they are more disposed to prioritize their health and lifespan, resulting in stricter compliance with vaccination protocols against bacterial and viral dangers. This cultural evolution effectively broadens the potential market for biologicals by ensuring a greater share of the pet population obtains regular care. The scale of this ownership base is significant; UK Pet Food's 'Pet Data Report 2024' from March 2024 noted that the United Kingdom's total pet population stood at 36 million, emphasizing the immense number of animals needing regular veterinary care.

Simultaneously, rising spending on veterinary healthcare supports the market by enabling the uptake of premium and innovative vaccine products. The growing readiness of owners to dedicate substantial funds to medical services helps offset potential cost hurdles, fostering value growth within the industry. According to the American Pet Products Association's 'State of the Industry 2025' report released in March 2025, annual expenditures on veterinary care and product sales in the United States were anticipated to hit $41.4 billion, signaling a strong commitment to animal wellness. This financial dedication is reinforced by active engagement with veterinary experts; Animal Medicines Australia's 'Pets in Australia 2025' report from September 2025 indicated that 89% of dogs and 75% of cats visited a veterinarian in the prior year, illustrating the high compliance levels that secure recurring revenue for manufacturers.

Market Challenge

The escalating cost of veterinary services constitutes a major barrier to the expansion of the global pet vaccine market. As the financial weight of routine animal healthcare increases, budget-conscious owners are frequently compelled to choose urgent medical treatments over preventative actions like vaccination. This economic pressure disrupts the continuity of care necessary for effective immunization regimens, causing a decrease in the total volume of vaccines administered. When wellness exams become too costly, owners often postpone these essential visits, leading to missed chances for veterinarians to provide required annual boosters and sustain immunity levels.

Consequently, this pattern of delayed maintenance leads to a direct contraction in market demand. When owners fail to maintain recommended vaccination schedules, it undermines herd immunity and stalls revenue generation for vaccine producers. Data from the American Veterinary Medical Association in 2025 showed that veterinary service prices rose by 5.7 percent, coinciding with a 3 percent year-over-year drop in patient visits. This link between increasing costs and reduced clinic attendance illustrates how affordability issues significantly hinder the industry's capacity to sustain steady growth rates in both developed and emerging regions.

Market Trends

The commercialization of therapeutic vaccines for chronic conditions is fundamentally transforming the Global Pet Vaccine Market by broadening the focus of immunization from infectious disease prevention to the active management of complex, non-infectious ailments such as oncology. Manufacturers are increasingly utilizing autologous and precision immunotherapy technologies to develop biologicals that prompt a companion animal's immune system to attack tumor-specific antigens. This clinical advancement offers veterinarians effective interventions for terminal conditions that previously had few options. For example, a February 2025 press release from Torigen Pharmaceuticals regarding 'New Hope For Pets In The Fight Against Cancer' reported that dogs with metastatic hemangiosarcoma treated with their targeted autologous cancer vaccine showed a 3.5-fold increase in overall survival compared to those receiving surgery alone, validating the rising reliance on therapeutic biologicals for aging pets.

At the same time, the shift toward recombinant and subunit vaccine platforms is altering the industry's manufacturing landscape as companies move away from conventional live-attenuated techniques to improve safety and production scalability. This trend emphasizes the creation of high-purity antigens and large-molecule biologicals, requiring significant capital investments in bioprocessing infrastructure to guarantee supply chain stability. This strategic move to advanced platform technologies is demonstrated by major industrial commitments; in May 2025, Merck Animal Health announced an investment of $895 million to expand its De Soto, Kansas facility to boost production capacity for large molecule vaccines and biologics. Such expenditures highlight the market's dedication to sophisticated delivery systems that provide enhanced potency and lower risks of adverse reactions in companion animals.

Key Market Players

  • Zoetis Inc.
  • Bioveta a.s
  • Hester Biosciences Limited
  • Boehringer Ingelheim International GmbH
  • Brilliant Bio Pharma Private Limited
  • Heska Corporation
  • Merck & Co., Inc.
  • Virbac S.A.
  • Zendal Group
  • Elanco Animal Health Incorporated

Report Scope

In this report, the Global Pet Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pet Vaccine Market, By Animal Type

  • Canine
  • Feline
  • Equine

Pet Vaccine Market, By Vaccination

  • Canine Family
  • Feline Family
  • Others

Pet Vaccine Market, By Mode Of Administration

  • Injectable Vaccines
  • Intranasal Vaccines

Pet Vaccine Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pet Vaccine Market.

Available Customizations:

Global Pet Vaccine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pet Vaccine Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Animal Type (Canine, Feline, Equine)
    • 5.2.2. By Vaccination (Canine Family, Feline Family, Others)
    • 5.2.3. By Mode Of Administration (Injectable Vaccines, Intranasal Vaccines)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Pet Vaccine Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Animal Type
    • 6.2.2. By Vaccination
    • 6.2.3. By Mode Of Administration
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Pet Vaccine Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Animal Type
        • 6.3.1.2.2. By Vaccination
        • 6.3.1.2.3. By Mode Of Administration
    • 6.3.2. Canada Pet Vaccine Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Animal Type
        • 6.3.2.2.2. By Vaccination
        • 6.3.2.2.3. By Mode Of Administration
    • 6.3.3. Mexico Pet Vaccine Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Animal Type
        • 6.3.3.2.2. By Vaccination
        • 6.3.3.2.3. By Mode Of Administration

7. Europe Pet Vaccine Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Animal Type
    • 7.2.2. By Vaccination
    • 7.2.3. By Mode Of Administration
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Pet Vaccine Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Animal Type
        • 7.3.1.2.2. By Vaccination
        • 7.3.1.2.3. By Mode Of Administration
    • 7.3.2. France Pet Vaccine Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Animal Type
        • 7.3.2.2.2. By Vaccination
        • 7.3.2.2.3. By Mode Of Administration
    • 7.3.3. United Kingdom Pet Vaccine Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Animal Type
        • 7.3.3.2.2. By Vaccination
        • 7.3.3.2.3. By Mode Of Administration
    • 7.3.4. Italy Pet Vaccine Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Animal Type
        • 7.3.4.2.2. By Vaccination
        • 7.3.4.2.3. By Mode Of Administration
    • 7.3.5. Spain Pet Vaccine Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Animal Type
        • 7.3.5.2.2. By Vaccination
        • 7.3.5.2.3. By Mode Of Administration

8. Asia Pacific Pet Vaccine Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Animal Type
    • 8.2.2. By Vaccination
    • 8.2.3. By Mode Of Administration
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Pet Vaccine Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Animal Type
        • 8.3.1.2.2. By Vaccination
        • 8.3.1.2.3. By Mode Of Administration
    • 8.3.2. India Pet Vaccine Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Animal Type
        • 8.3.2.2.2. By Vaccination
        • 8.3.2.2.3. By Mode Of Administration
    • 8.3.3. Japan Pet Vaccine Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Animal Type
        • 8.3.3.2.2. By Vaccination
        • 8.3.3.2.3. By Mode Of Administration
    • 8.3.4. South Korea Pet Vaccine Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Animal Type
        • 8.3.4.2.2. By Vaccination
        • 8.3.4.2.3. By Mode Of Administration
    • 8.3.5. Australia Pet Vaccine Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Animal Type
        • 8.3.5.2.2. By Vaccination
        • 8.3.5.2.3. By Mode Of Administration

9. Middle East & Africa Pet Vaccine Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Animal Type
    • 9.2.2. By Vaccination
    • 9.2.3. By Mode Of Administration
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Pet Vaccine Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Animal Type
        • 9.3.1.2.2. By Vaccination
        • 9.3.1.2.3. By Mode Of Administration
    • 9.3.2. UAE Pet Vaccine Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Animal Type
        • 9.3.2.2.2. By Vaccination
        • 9.3.2.2.3. By Mode Of Administration
    • 9.3.3. South Africa Pet Vaccine Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Animal Type
        • 9.3.3.2.2. By Vaccination
        • 9.3.3.2.3. By Mode Of Administration

10. South America Pet Vaccine Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Animal Type
    • 10.2.2. By Vaccination
    • 10.2.3. By Mode Of Administration
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Pet Vaccine Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Animal Type
        • 10.3.1.2.2. By Vaccination
        • 10.3.1.2.3. By Mode Of Administration
    • 10.3.2. Colombia Pet Vaccine Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Animal Type
        • 10.3.2.2.2. By Vaccination
        • 10.3.2.2.3. By Mode Of Administration
    • 10.3.3. Argentina Pet Vaccine Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Animal Type
        • 10.3.3.2.2. By Vaccination
        • 10.3.3.2.3. By Mode Of Administration

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Pet Vaccine Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Zoetis Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Bioveta a.s
  • 15.3. Hester Biosciences Limited
  • 15.4. Boehringer Ingelheim International GmbH
  • 15.5. Brilliant Bio Pharma Private Limited
  • 15.6. Heska Corporation
  • 15.7. Merck & Co., Inc.
  • 15.8. Virbac S.A.
  • 15.9. Zendal Group
  • 15.10. Elanco Animal Health Incorporated

16. Strategic Recommendations

17. About Us & Disclaimer